According to the recent study the Middle Eastern and North African active pharmaceutical ingredient (API) market is projected to reach an estimated $5 billion by 2030 from $3 billion in 2023 at a CAGR of 5% from 2023 to 2030. Growth in this market is primarily driven by pharmaceutical production and research and development of new drugs.
A more than 150 page
report to understand trends, opportunities and forecast in Middle Eastern and
North African active pharmaceutical ingredient (API) market by synthesis type
(synthetic chemical, biotech and biologics, plant extracts, fermentation, and
others), manufacturer type (captive API and merchant API), therapeutic area (cardiology,
oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment,
anti-inflammatory, and others), product form (liquid API and powder API),
molecule type (large molecule and small molecule), and drug type (branded,
generic, and over-the-counter).
Lucintel forecasts that
synthetic chemical will remain the largest segment over the forecast period due
to continuous research and development activities and growing demand of
synthetic chemical APIs in therapeutic areas.
Within this market,
cardiology will remain the largest therapeutic area segment over the forecast
period due to increasing cardiovascular diseases and increase in geriatric
population.
Download report by clicking on
Middle Eastern and North African
active pharmaceutical ingredient (API) market.
Pfizer, Teva
Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co.,
BASF, Julphar, and AbbVie are the major
suppliers in the Middle Eastern and North African active pharmaceutical
ingredient (API) providers.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1 972.636.5056
Explore Our Latest Publications
No comments:
Post a Comment